News Bayer gets first approval for stroke drug asundexian Bayer's oral Factor XIa inhibitor asundexian has been cleared in its first market, China, for secindary stroke prevention.
News ESMO26: Bayer's Nubeqa finds new prostate cancer role Bayer's prostate cancer drug Nubeqa has reduced the risk of the disease spreading or death by 58% in patients at high risk of disease recurrence.
News Bayer pledges $2.2bn to US manufacturing facility Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.
News Bayer names Christoph Koenen as its new CMO Bayer has looked internally for its chief medical officer, appointing Christoph Koenen to the post alongside his current clinical development role.
News Bayer's Kerendia gets broader use in diabetic kidney disease Bayer's fast-growing Kerendia has had its label extended in the US to include chronic kidney disease associated with type 1 diabetes.
News Dren Bio pockets $350m for rare blood cancer programme Dren Bio has closed a sizeable private financing round, raising $350m for pivotal trials of a possible first-in-class therapy for rare blood cancers.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
